Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis

Yu, Aijun; Zhao, Luwen; Kang, Qingmin; Li, Jian; Chen, Kai; Fu, Hua

doi:10.1016/j.trsl.2020.05.010

Cited by 32 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIF1α-mediated H19 overexpression in CCC cells promoted proliferation, migration, and invasion via regulating the miR-612/Bcl-2 axis ( Fig. 1 W ) 74 . Overall, these data confirmed that H19 had an oncogenic activity in GBC and CCC and represented a promising diagnostic target.…”

Section: H19 In Various Human Cancersmentioning

confidence: 97%

LncRNA H19: A novel oncogene in multiple cancers

Yang¹,

Qi²,

Fei³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a series of non-coding RNAs that lack open reading frameworks. Accumulating evidence suggests important roles for lncRNAs in various diseases, including cancers. Recently, lncRNA H19 (H19) became a research focus due to its ectopic expression in human malignant tumors, where it functioned as an oncogene. Subsequently, H19 was confirmed to be involved in tumorigenesis and malignant progression in many tumors and had been implicated in promoting cell growth, invasion, migration, epithelial-mesenchymal transition, metastasis, and apoptosis. H19 also sequesters some microRNAs, facilitating a multilayer molecular regulatory mechanism. In this review, we summarize the abnormal overexpression of H19 in human cancers, which suggests wide prospects for further research into the diagnosis and treatment of cancers.

show abstract

Section: H19 In Various Human Cancersmentioning

confidence: 97%

LncRNA H19: A novel oncogene in multiple cancers

Yang¹,

Qi²,

Fei³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…H19 was found to be overexpressed under the effect of the transcription factor hypoxia-inducible Factor 1α (HIF1α). Additionally, H19 was found to promote Bcl-2 expression by downregulating miR-612 expression, which promoted cholangiocarcinoma ( Yu et al, 2020 ).…”

Section: Oncogenic Signaling Pathways Regulated By H19 In Cancermentioning

confidence: 99%

“…MiR-675, one of the targeted miRNAs of H19, is embedded in H19’s first exon, and H19 has been shown to inhibit the growth of the placenta before birth by regulating the processing of miR-675. H19 can also interact with other miRNAs, such as miR-326 ( Wei et al, 2019 ), miR-29a ( Cheng et al, 2019 ), miR-124-3p ( Liu et al, 2019 ), miR-152-3p ( Zheng et al, 2020 ), miR-22-3p ( Gan et al, 2019 ), miR-29b-3p ( Zhong et al, 2021 ), miR-193a-3p ( Ma et al, 2018 ), miR-612 ( Yu et al, 2020 ), to regulate biological processes in various types of cells by modulating the expression of downstream target factors, including twist family bHLH transcription factor 1 (TWIST1), thymine DNA glycosylase, integrin β3 (ITGB3), bromodomain containing protein 4 (BRD4), Snail1, high mobility group box 1 (HMGB1), presenilin-1 (PSEN1), and Bcl-2. Secondly, H19 is involved in regulating different processes in various types of cells by interacting with different proteins, such as methyl-CpG-binding domain protein 1 (MBD1) ( Monnier et al, 2013 ; Zhang et al, 2017 ), polypyrimidine tract-binding protein 1 (PTBP1) ( Liu et al, 2018 ), enhancer of zeste homolog 2 (EZH2) ( Luo et al, 2013 ), IGF2 mRNA-binding protein 1 (IGF2BP1) ( Runge et al, 2000 ), p53 ( Yang et al, 2012 ), K homology-type splicing regulatory protein (KSRP) ( Giovarelli et al, 2014 ), zinc finger E-box-binding homeobox 1 (ZEB1) ( Song et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long noncoding RNA H19 (H19) is an imprinting gene with only maternal expression that is involved in regulating different processes in various types of cells. Previous studies have shown that abnormal H19 expression is involved in many pathological processes, such as cancer, mainly through sponging miRNAs, interacting with proteins, or regulating epigenetic modifications. Accumulating evidence has shown that several oncogenic signaling pathways lead to carcinogenesis. Recently, the regulatory relationship between H19 and oncogenic signaling pathways in various types of cancer has been of great interest to many researchers. In this review, we discussed the key roles of H19 in cancer development and progression via its regulatory function in several oncogenic signaling pathways, such as PI3K/Akt, canonical Wnt/β-catenin, canonical NF-κB, MAPK, JAK/STAT and apoptosis. These oncogenic signaling pathways regulated by H19 are involved in cell proliferation, proliferation, migration and invasion, angiogenesis, and apoptosis of various cancer cells. This review suggests that H19 may be a novel therapeutic target for cancers treatment by regulating oncogenic signaling pathways.

show abstract

“…Several studies demonstrated that miRNA-612 (miR-612) exerts tumor-suppressive effects through targeting multiple anti-apoptotic genes, such as bromodomain-containing protein 4 ( BRD4 ), AKT serine/threonine kinase 2 ( AKT2 ), and NIN1/PSMD8 binding protein 1 homolog ( NOB1 ) [ 42 , 43 , 44 ]. Moreover, miR-612 can negatively regulate the expression of B-cell CLL/lymphoma 2 ( BCL2 ) via interacting with the 3′ untranslated region (3′ UTR) [ 45 ]. In this study, it was further shown that H19 is induced by HIF-1α and renders miR-612 inactive, resulting in the upregulation of BCL2.…”

Section: Lncrnas Controlled By Hypoxia and Hifsmentioning

confidence: 99%

“…In this study, it was further shown that H19 is induced by HIF-1α and renders miR-612 inactive, resulting in the upregulation of BCL2. Moreover, the knockdown of HIF-1α significantly restrains the growth of cholangiocarcinoma in vivo, along with miR-612 upregulation and BCL2 downregulation [ 45 ] ( Figure 1 and Table 1 ).…”

Section: Lncrnas Controlled By Hypoxia and Hifsmentioning

confidence: 99%

The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers

Son

Yun

Song

et al. 2021

IJMS

View full text Add to dashboard Cite

Hypoxia is one of the representative microenvironment features in cancer and is considered to be associated with the dismal prognosis of patients. Hypoxia-driven cellular pathways are largely regulated by hypoxia-inducible factors (HIFs) and notably exert influence on the hallmarks of cancer, such as stemness, angiogenesis, invasion, metastasis, and the resistance towards apoptotic cell death and therapeutic resistance; therefore, hypoxia has been considered as a potential hurdle for cancer therapy. Growing evidence has demonstrated that long noncoding RNAs (lncRNAs) are dysregulated in cancer and take part in gene regulatory networks owing to their various modes of action through interacting with proteins and microRNAs. In this review, we focus attention on the relationship between hypoxia/HIFs and lncRNAs, in company with the possibility of lncRNAs as candidate molecules for controlling cancer.

show abstract

Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis

Cited by 32 publications

References 36 publications

LncRNA H19: A novel oncogene in multiple cancers

LncRNA H19: A novel oncogene in multiple cancers

Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways

The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers

Contact Info

Product

Resources

About